12 May 2021 in Science Translational Medicine
Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol and are used for treatment of dyslipidemia. Current PCSK9 inhibitors are administered via subcutaneous injection. We present a highly potent, chemically modified PCSK9 antisense oligonucleotide (ASO) with potential for oral delivery. Past attempts at oral delivery using earlier-generation ASO chemistries and transient permeation enhancers provided encouraging data, suggesting that improving potency of the ASO could make oral delivery a reality. The constrained ethyl chemistry and liver targeting enabled by N-acetylgalactosamine conjugation make this ASO highly potent. A single subcutaneous dose of 90 mg reduced PCSK9 by >90% in humans with elevated LDL cholesterol and a monthly subcutaneous dose of around 25 mg is predicted to reduce PCSK9 by 80% at steady state. To investigate the feasibility of oral administration, the ASO was coformulated in a tablet with sodium caprate as permeation enhancer. Repeated oral daily dosing in dogs resulted in a bioavailability of 7% in the liver (target organ), about fivefold greater than the plasma bioavailability. Target engagement after oral administration was confirmed by intrajejunal administration of a rat-specific surrogate ASO in solution with the enhancer to rats and by plasma PCSK9 and LDL cholesterol lowering in cynomolgus monkey after tablet administration. On the basis of an assumption of 5% liver bioavailability after oral administration in humans, a daily dose of 15 mg is predicted to reduce circulating PCSK9 by 80% at steady state, supporting the development of the compound for oral administration to treat dyslipidemia.
14 February 2017 in American Journal of Cardiovascular Drugs
5 August 2025 in CPT: Pharmacometrics & Systems Pharmacology
In this second part of a case study on the practical use of model‐informed drug development (MIDD), we describe the clinical development of AZD8233, a novel proprotein convertase subtilisin/kexin type 9 (PCSK9) antisense oligonucleotide, from phase 2b to the start of phase 3. The case study exemplifies the use of MIDD to answer key design questions for the phase 3 program, including the design of a pivotal phase 3 study, a head‐to‐head study, and a cardiovascular outcome study informed by model‐averaging analysis. Extensive phase 3 study simulations assessed the impact of drop‐out, readout timing, dose frequency, and analysis method on study outcomes. The final phase 3 design assumed around 1% monthly drop‐out (based on other PCSK9 inhibitor trials), used an EMA/FDA‐approved analysis method, and set the primary readout at week 16. A simulated study predicted a reduction in low‐density lipoprotein cholesterol (LDL‐C) by week 16 of −69% with AZD8233 60 mg every 4 weeks. A virtual head‐to‐head study showed AZD8233 lowered LDL‐C by 27% more than an active competitor (inclisiran) at day 270. Predicted cardiovascular relative risk reduction (RRR) for AZD8233 on top of statins ranged from 24% to 49% based on model choice; a model‐averaging approach predicted an RRR of 27% assuming 63% LDL‐C reduction from a 130 mg/dL baseline. This case study highlights the importance of cross‐functional collaboration and other key MIDD enablers to ensure that MIDD extends beyond a simple simulation exercise and is instead considered an integral part of drug development dedicated to quantitative decision making.